Content about DUBLIN

April 18, 2014

Actavis on Friday announced that it has entered into agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration.

DUBLIN — Actavis on Friday announced that it has entered into agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration. The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech. Financial terms of the agreements were not disclosed.

April 18, 2014

Actavis and Forest Laboratories on Thursday announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Forest.

DUBLIN  — Actavis and Forest Laboratories on Thursday announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Forest. 

The effect of the second request is to extend the waiting period until 30 days after Actavis and Forest have substantially complied with the request, unless that period is extended voluntarily by the parties or terminated sooner by the FTC.  

April 16, 2014

Among severely obese people, vitamin D may make the difference between an active and a more sedentary lifestyle, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism on Tuesday.

WASHINGTON — Among severely obese people, vitamin D may make the difference between an active and a more sedentary lifestyle, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism on Tuesday.

The study found severely obese people who also were vitamin D-deficient walked slower and were less active overall than their counterparts who had healthy vitamin D levels. Poor physical functioning can reduce quality of life and even shorten lifespans.

April 15, 2014

Actavis on Tuesday announced that it has entered into an agreement with Mylan and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).

DUBLIN — Actavis on Tuesday announced that it has entered into an agreement with Mylan and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).

Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess FE under its pending abbreviated new drug application beginning on April 1, 2015.

April 7, 2014

Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion.

DUBLIN — Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion. The transaction was unanimously approved by the boards of directors of both companies. Subject to customary closing conditions, the transaction currently is expected to be completed in the third calendar-quarter of 2014.

March 26, 2014

Actavis and Valeant Pharmaceuticals International announced that the Food and Drug Administration approved the new drug application for Metronidazole 1.3% vaginal gel. The antibiotic is used for the treatment of bacterial vaginosis, an infection caused by an imbalance in the normal bacteria of vagina.

DUBLIN and LAVAL, Quebec — Actavis and Valeant Pharmaceuticals International announced that the Food and Drug Administration approved the new drug application for Metronidazole 1.3% vaginal gel.

The antibiotic is used for the treatment of bacterial vaginosis, an infection caused by an imbalance in the normal bacteria of vagina. It's the most common vaginal infection in women ages 15 years to 44 years. Metronidazole 1.3% provides a single-dose treatment that is packaged in a pre-filled disposable applicator.

March 26, 2014

Perrigo announced that its Nutritionals segment is partnering with KanPak to manufacture store brand adult nutritional drinks comparable to Ensure products.

DUBLIN — Perrigo on Wednesday announced that its Nutritionals segment is partnering with KanPak to manufacture store brand adult nutritional drinks comparable to Ensure products. KanPak is a supplier of beverages and desserts using aseptic processing technology. 

March 21, 2014

Actavis earlier this week announced that it has entered into an agreement with Noven Pharmaceuticals to settle all outstanding patent litigation related to Actavis' generic version of Daytrana (methylphenidate transdermal system).

DUBLIN — Actavis earlier this week announced that it has entered into an agreement with Noven Pharmaceuticals to settle all outstanding patent litigation related to Actavis' generic version of Daytrana (methylphenidate transdermal system). Daytrana is a CNS stimulant indicated for the treatment of attention deficit hyperactivity disorder.

March 20, 2014

Mallinckrodt, a specialty pharmaceuticals company, announced the completion of its acquisition of Cadence Pharmaceuticals for approximately $1.4 billion.

DUBLIN — Mallinckrodt, a specialty pharmaceuticals company, announced the completion of its acquisition of Cadence Pharmaceuticals for approximately $1.4 billion.

March 18, 2014

Mallinckrodt Plc last week announced that the Food and Drug Administration approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), for the management of acute pain severe enough that it requires opioid treatment.

DUBLIN — Mallinckrodt Plc last week announced that the Food and Drug Administration approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), for the management of acute pain severe enough that it requires opioid treatment.

The drug also is indicated for patients for whom alternative treatments have shown to be ineffective. Xartemis XR, previously known as MNK-795, is the first and only extended-release oral combination of two clinically proven pain medications — oxycodone and acetaminophen.

March 17, 2014

A recent audience-research study conducted by Nielsen found that among Cardinal Health's digital advertising network for retail pharmacies, called Pharmacy Health Network, half of viewers surveyed (49%) indicated that they felt encouraged to discuss a product or brand they had seen on Pharmacy Health Network with their pharmacist, and 48% indicated that after seeing ads on Pharmacy Health Network, they felt motivated to discuss those products or brands with their physicians.

DUBLIN, Ohio — A recent audience-research study conducted by Nielsen found that among Cardinal Health's digital advertising network for retail pharmacies, called Pharmacy Health Network, half of viewers surveyed (49%) indicated that they felt encouraged to discuss a product or brand they had seen on Pharmacy Health Network with their pharmacist, and 48% indicated that after seeing ads on Pharmacy Health Network, they felt motivated to discuss those products or brands with their physicians.

March 13, 2014

The Cardinal Health Foundation and the Ohio State University College of Pharmacy have announced the introduction of the Medication Safety toolkit, the fifth in a series of interactive toolkits designed to help reduce the abuse of prescription drugs.

DUBLIN, Ohio — The Cardinal Health Foundation and the Ohio State University College of Pharmacy have announced the introduction of the Medication Safety toolkit, the fifth in a series of interactive toolkits designed to help reduce the abuse of prescription drugs.

The Medication Safety toolkit is designed to arm parents, teachers, organizational leaders and health professionals across the country with the necessary resources to discuss the issue of medication safety with elementary-aged children.

March 13, 2014

Perrigo announced the launch of methazolamide tablets, the generic version of Neptazane tablets. The product is a component of the rights the company received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals and its affiliates last year.

DUBLIN — Perrigo announced the launch of methazolamide tablets, the generic version of Neptazane tablets. The product is a component of the rights the company received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals and its affiliates last year.

March 3, 2014

Cardinal Health Specialty Solutions on Monday announced the acquisition of privately held Sonexus Health, a Dallas-based company that offers a range of patient access and specialty commercialization services.

DUBLIN, Ohio — Cardinal Health Specialty Solutions on Monday announced the acquisition of privately held Sonexus Health, a Dallas-based company that offers a range of patient access and specialty commercialization services.

February 28, 2014

Perrigo on Friday announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global for $51 million in cash.

DUBLIN — Perrigo on Friday announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global for $51 million in cash. 

The products are primarily sold through the mass retail channel and include the Herron range of analgesics, vitamins and supplements. This basket of products is expected to generate at least $20 million in annual revenue.

February 18, 2014

Actavis and Forest Labs. announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion, or $89.48 per Forest share ($26.04 in cash and 0.3306 Actavis shares for each share of Forest common stock).

DUBLIN — Actavis and Forest Labs. on Tuesday announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion, or $89.48 per Forest share ($26.04 in cash and 0.3306 Actavis shares for each share of Forest common stock). The per share consideration represents a premium of approximately 25% per share over Forest’s stock price, and a premium of approximately 31% over Forest’s 10-day volume weighted average stock price, as of the close of trading on Feb.

February 12, 2014

Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash.

DUBLIN — Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price of $10.62 per share for Cadence Pharmaceuticals.

January 31, 2014

Actavis on Friday announced a realignment of its global strategic business structure to maximize the company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth.

DUBLIN — Actavis on Friday announced a realignment of its global strategic business structure to maximize the company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth. 

January 30, 2014

The loss of the Walgreens contract was a key consideration in Cardinal Health's 12% decline in overall revenue for the company's second quarter 2014, George Barrett, Cardinal Health chairman and CEO, told analysts Thursday morning.

DUBLIN, Ohio — The loss of the Walgreens contract was a key consideration in Cardinal Health's 12% decline in overall revenue for the company's second quarter 2014, George Barrett, Cardinal Health chairman and CEO, told analysts Thursday morning. Revenue totaled $22.2 billion. The loss of the Walgreens contract totaled $5 billion. 

But Cardinal Health is bullish regarding its future. Cardinal Health increased its outlook for the next six months, raising its non-GAAP EPS range to $3.75 to $3.85. 

January 28, 2014

Actavis announced that it has signed and completed an agreement for Zhejiang Chiral Medicine Chemicals Co. to acquire Actavis' interest in Actavis (Foshan) Pharmaceuticals Co., an Actavis subsidiary based in Foshan, China.

DUBLIN — Actavis last week announced that it has signed and completed an agreement for Zhejiang Chiral Medicine Chemicals Co. to acquire Actavis' interest in Actavis (Foshan) Pharmaceuticals Co., an Actavis subsidiary based in Foshan, China.  

Actavis intends to continue further commercial operations in China in collaboration with its preferred business partners.

January 24, 2014

Perrigo announced that it received final approval from the Food and Drug Administration for repaglinide tablets — a generic version of Prandin tablets.

DUBLIN — Perrigo Co. announced that it received final approval from the Food and Drug Administration for repaglinide tablets — a generic version of Prandin tablets — in 1-mg and 2-mg strengths. The company has started shipment of the drug. Perrigo previously launched the 0.5-mg strength in 2013.

January 22, 2014

HealthSpot has formed a strategic partnership with MedAvail Technologies, which created the MedAvail MedCenter telepharmacy kiosk, to enable HealthSpot station locations to provide pharmacy services in addition to acute care telehealth services in locations where there is no retail pharmacy, such as employer sites and community locations.

DUBLIN, Ohio — HealthSpot has formed a strategic partnership with MedAvail Technologies, which created the MedAvail MedCenter telepharmacy kiosk, to enable HealthSpot station locations to provide pharmacy services in addition to acute care telehealth services in locations where there is no retail pharmacy, such as employer sites and community locations.
 

January 21, 2014

Actavis Pharma recently announced that it intends to enter into an agreement for Aurobindo Pharma to acquire Actavis' generics commercial operations in seven markets in Western Europe.

DUBLIN — Actavis Pharma recently announced that it intends to enter into an agreement for Aurobindo Pharma to acquire Actavis' generics commercial operations in seven markets in Western Europe. The transaction is conditional on certain antitrust approvals and completion of employee consultation processes. 

January 21, 2014

Actavis confirmed that the U.S. District Court for the District of New Jersey found United States Patent No. 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals and Amneal Pharmaceuticals Abbreviated New Drug Applications (ANDAs) for generic versions of Actavis' Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets).

DUBLIN — Actavis last week confirmed that the U.S. District Court for the District of New Jersey found United States Patent No. 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals and Amneal Pharmaceuticals Abbreviated New Drug Applications (ANDAs) for generic versions of Actavis' Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets).  

Lo Loestrin Fe is a prescription birth control pill used for the prevention of pregnancy.

January 15, 2014

In its newest educational program, the Generation Rx Initiative mixes online learning with video games released Wednesday to promote learning about the dangers of prescription drug misuse and abuse.

DUBLIN, Ohio — In its newest educational program, the Generation Rx Initiative mixes online learning with video games released Wednesday to promote learning about the dangers of prescription drug misuse and abuse. The game can be integrated into parents' and teachers' National Drug Facts Week efforts Jan. 27 to Feb. 2. NDFW is a health observance week for teens that aims to shatter the myths about drugs and drug abuse through community-based events and educational activities on the Web, on television and through contests.